Trince is a spin-off company from Ghent University dedicated to advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company's LumiPore transfection platform, which is covered by a portfolio of pending patents, combines laser exposure with photothermal nanoparticles to convert light energy into heat to transiently permeabilize the cellular plasma membrane. It can be used to deliver a wide variety of effector molecules (e.g. nucleic acids or proteins) into virtually any cell type, including hard-to-transfect cells such as immune cells for cell therapies. The technology not only makes it easier to bring genetic material into cells in high-throughput. It also ensures that this is done in a gentle manner, maximizing the therapeutic quality of the final cell product. www.trincebio.com
Company Details
- Employees
- 18
- Address
- Ottergemsesteenweg-Zuid 731, Ghent,flemish Region 9000,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.trincebio.com
- Keywords
- Operations jobs.
- HQ
- Ghent, Flemish Region
Trince Questions
Trince's website is http://www.trincebio.com
Trince's LinkedIn profile is https://be.linkedin.com/company/trince
Trince has
18 employees.
View email and phone details for 18
employees at Trince.
Trince's industry is
Biotechnology Research
Trince's top competitors are
Rheavita Bv,
Abscint,
Ovizio,
Biolizard,
Conveyxo,
Novalis Biotech,
Legend Biotech,
Myneo Therapeutics,
Confo Therapeutics,
Ohmx.bio.
Trince's categories are Biotechnology Research
